Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. With unique fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The current Portfolio Grader recommendation on the shares has been in place for the last month.

AstraZeneca Plc (NYSE:AZN) is a $83.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the ranking for AZN by Portfolio Grader places it 37 among the 132 companies in this industry group, giving it an above-average position. AZN is ranked in the top half of the sector with a ranking of 267 among the 782 companies in the sector and number 1,662 in the 5000 company Portfolio Grader company universe.

Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

AstraZeneca Plc (NYSE:AZN) is ranked as a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methods. The shares have been upgraded from a Hold to a Buy in the last week.

Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Hold. Using Louis Navellier's investing methodology, this analytical tool assesses stocks with fundamental and quantitative analytical tools. AZN has maintained this ranking for the last month.

AstraZeneca Plc (NYSE:AZN) is a component of the 135 company Pharmaceuticals GICS industry group, which is a segment of the 783 company GICS Health Care sector. AZN's market value is $87.6 billion which falls in the top decile in its industry group. The ranking for AZN by Portfolio Grader places it 49 among the 135 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 301 among the 783 companies in the sector, and number 2,076 in the nearly 5,000 company Portfolio Grader universe.

Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Hold. With exclusive fundamental and quantitative analytical tools developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Currently, AstraZeneca Plc (NYSE:AZN) has a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. AZN has maintained this ranking for 2 months.